AU2017362328B2 - Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension - Google Patents

Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension Download PDF

Info

Publication number
AU2017362328B2
AU2017362328B2 AU2017362328A AU2017362328A AU2017362328B2 AU 2017362328 B2 AU2017362328 B2 AU 2017362328B2 AU 2017362328 A AU2017362328 A AU 2017362328A AU 2017362328 A AU2017362328 A AU 2017362328A AU 2017362328 B2 AU2017362328 B2 AU 2017362328B2
Authority
AU
Australia
Prior art keywords
substituted
glutamine
unsubstituted alkyl
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017362328A
Other languages
English (en)
Other versions
AU2017362328A1 (en
Inventor
Joshua P. Fessel
L. Jackson Roberts
James West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2017362328A1 publication Critical patent/AU2017362328A1/en
Application granted granted Critical
Publication of AU2017362328B2 publication Critical patent/AU2017362328B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017362328A 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension Active AU2017362328B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
US62/422,486 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (2)

Publication Number Publication Date
AU2017362328A1 AU2017362328A1 (en) 2019-06-27
AU2017362328B2 true AU2017362328B2 (en) 2022-03-31

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017362328A Active AU2017362328B2 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Country Status (9)

Country Link
US (2) US20190314302A1 (OSRAM)
EP (2) EP4385576A3 (OSRAM)
JP (1) JP7383285B2 (OSRAM)
CN (1) CN110177463B (OSRAM)
AU (1) AU2017362328B2 (OSRAM)
ES (1) ES2981715T3 (OSRAM)
HU (1) HUE067036T2 (OSRAM)
PL (1) PL3541185T3 (OSRAM)
WO (1) WO2018093936A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
WO2020154724A1 (en) 2019-01-25 2020-07-30 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
BR112022014876A2 (pt) * 2020-01-27 2022-12-13 Univ Vanderbilt Sequestradores de isolevuglandinas/isocetais que têm mitocôndria como alvo e usos dos mesmos
JP2023545304A (ja) * 2020-10-13 2023-10-27 ヴァンダービルト ユニバーシティー 腎傷害による腸リンパ管の乱れを予防する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157501A1 (en) * 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224566A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
JP5132109B2 (ja) * 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
EP3111933B1 (en) * 2006-11-13 2019-09-04 PCB Associates, Inc. Prophylaxis or treatment of glomerulosclerosis
US8314015B2 (en) * 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension
KR20140050661A (ko) * 2011-07-12 2014-04-29 벤더르빌트 유니버시티 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법
WO2013142303A1 (en) * 2012-03-19 2013-09-26 Lycera Corporation Methods and compositions for detecting immune system activation
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157501A1 (en) * 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases

Also Published As

Publication number Publication date
JP7383285B2 (ja) 2023-11-20
EP3541185A4 (en) 2020-06-24
WO2018093936A1 (en) 2018-05-24
EP3541185C0 (en) 2024-04-24
HUE067036T2 (hu) 2024-09-28
ES2981715T3 (es) 2024-10-10
CN110177463B (zh) 2022-03-08
PL3541185T3 (pl) 2024-08-12
AU2017362328A1 (en) 2019-06-27
JP2019536778A (ja) 2019-12-19
CN110177463A (zh) 2019-08-27
EP4385576A2 (en) 2024-06-19
EP3541185A1 (en) 2019-09-25
US20250381155A1 (en) 2025-12-18
US20190314302A1 (en) 2019-10-17
EP4385576A3 (en) 2024-09-04
EP3541185B1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US20250381155A1 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
US20240189332A1 (en) Compositions for the treatment of fibrosis
US20220016136A1 (en) Compositions and methods for the treatment of liver disorders
JP2017036341A (ja) 癌細胞においてアポトーシスを誘導する方法および使用
US10894035B2 (en) Use of indole compounds to stimulate the immune system
EP2862572B1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
US20220193053A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
TWI472519B (zh) 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
HK40107155A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
US8729026B2 (en) Method for inhibiting autophagy of motor neurons
CN118892485A (zh) 凡德他尼及其药学上可接受的盐与硝苯地平及其药学上可接受的盐联合制备治疗癌症和长q-t间期综合症的药物中的用途
HK40006700A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700B (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
US20220162240A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers
NO20130284A1 (no) Fremgangsmater og sammensetninger for behandling av cancermetastase
Cairns et al. Cystinosis and its treatment
CN106507666A (zh) 1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉状瘤病的用途
EP4252750A1 (en) Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease
US9757356B2 (en) Composition comprising bio compound for treating cardiovascular disease
US20210323949A1 (en) Compounds and methods for inhibition of multiple myeloma
WO2025149089A1 (zh) 用于镇静的组合物和方法
AU2021214090A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)